Literature DB >> 2464954

Intermediate filament expression in astrocytic neoplasms.

M Cosgrove1, P L Fitzgibbons, A Sherrod, P T Chandrasoma, S E Martin.   

Abstract

Immunohistochemical analysis of 30 paraffin-embedded astrocytic neoplasms was performed to correlate the expression of intermediate filament proteins with histologic subtype. Each tumor was studied with monoclonal antibodies to keratin, vimentin, desmin, 200-kd neurofilament protein, and glial fibrillary acidic protein (GFAP). Immunoreactivity with the anti-keratin monoclonal antibodies AE1 and AE3 was demonstrated in 24 cases (80%) including 4 of 6 (66%) well-differentiated astrocytomas (WDAs), 10 of 12 (83%) anaplastic astrocytomas (ANAs), and 10 of 12 (83%) glioblastomas multiforme (GBMs). These cases were further studied with the monoclonal antikeratin antibodies 34 beta E12 and 34 beta H11. Of the 24 AE1/AE3-positive cases, 14 (58%) reacted with 34 beta E12. None of the cases was reactive with 34 beta H11. Vimentin expression was demonstrated in 24 cases (80%), including 2 of 6 (33%) WDAs, 11 of 12 (92%) ANAs, and 11 of 12 (92%) GBMs. Coexpression of keratin and vimentin was observed in 20 cases (67%), including 2 of 6 WDAs, 9 of 12 (75%) ANAs, and 9 of 12 (75%) GBMs. Immunoreactivity with GFAP antibody was present in all 30 (100%) cases, but none of the tumors was reactive with antibodies to desmin or 200-kd neurofilament protein. These findings demonstrate that expression of both keratin and vimentin intermediate filaments is common in astrocytic neoplasms regardless of histologic grade.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2464954     DOI: 10.1097/00000478-198902000-00007

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

1.  Diagnosis of malignant glioma: role of neuropathology.

Authors:  Daniel J Brat; Richard A Prayson; Timothy C Ryken; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

2.  Expression of cytokeratins in glioblastoma multiforme.

Authors:  Tadashi Terada
Journal:  Pathol Oncol Res       Date:  2015-01-30       Impact factor: 3.201

3.  Morphological, immunocytochemical and growth characteristics of three human glioblastomas established in vitro.

Authors:  T Bilzer; D Stavrou; E Dahme; E Keiditsch; K F Bürrig; A P Anzil; W Wechsler
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

4.  Biochemical correlates to cortical dysplasia, gliosis, and astrocytoma infiltration in human epileptogenic cortex.

Authors:  A Hamberger; E Bock; C Nordborg; B Nyström; H Silfvenius; S Wang; K G Haglid
Journal:  Neurochem Res       Date:  1993-04       Impact factor: 3.996

5.  A morphological and immunohistochemical study of human retinal pigment epithelial cells, retinal glia, and fibroblasts grown on Gelfoam matrix in an organ culture system. A comparison of structural and nonstructural proteins and their application to cell type identification.

Authors:  S A Vinores; M M Herman; S F Hackett; P A Campochiaro
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-05       Impact factor: 3.117

6.  Prognostic significance of neuronal marker expression in glioblastomas.

Authors:  Kyung-Hwa Lee; Kyung-Joo Kang; Kyung-Sub Moon; Tae-Young Jung; Shin Jung; Jae-Hyoo Kim; Hyung-Seok Kim; Min-Cheol Lee
Journal:  Childs Nerv Syst       Date:  2012-08-26       Impact factor: 1.475

7.  An epithelium-type cytoskeleton in a glial cell: astrocytes of amphibian optic nerves contain cytokeratin filaments and are connected by desmosomes.

Authors:  E Rungger-Brändle; T Achtstätter; W W Franke
Journal:  J Cell Biol       Date:  1989-08       Impact factor: 10.539

Review 8.  Human astrocytes in the diseased brain.

Authors:  Elena Dossi; Flora Vasile; Nathalie Rouach
Journal:  Brain Res Bull       Date:  2017-02-13       Impact factor: 4.077

9.  Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression.

Authors:  Hinda Najem; Martina Ott; Cynthia Kassab; Arvind Rao; Ganesh Rao; Anantha Marisetty; Adam M Sonabend; Craig Horbinski; Roel Verhaak; Anand Shankar; Santhoshi N Krishnan; Frederick S Varn; Víctor A Arrieta; Pravesh Gupta; Sherise D Ferguson; Jason T Huse; Gregory N Fuller; James P Long; Daniel E Winkowski; Ben A Freiberg; Charles David James; Leonidas C Platanias; Maciej S Lesniak; Jared K Burks; Amy B Heimberger
Journal:  JCI Insight       Date:  2022-05-09

10.  The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.

Authors:  Rebekah Baskin; Sung O Park; György M Keserű; Kirpal S Bisht; Heather L Wamsley; Peter P Sayeski
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.